Pfizer Inc. logo

Pfizer Inc. (PFE)

Market Open
16 Dec, 14:44
NYSE NYSE
$
25. 75
-0.7
-2.66%
$
146.18B Market Cap
14.55 P/E Ratio
1.68% Div Yield
9,334,312 Volume
1.43 Eps
$ 26.45
Previous Close
Day Range
25.71 26.5
Year Range
20.92 27.69
Want to track PFE and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 48 days
Want $1,000 in Dividend Income? Here's How Much You Have to Invest in Pfizer Stock

Want $1,000 in Dividend Income? Here's How Much You Have to Invest in Pfizer Stock

Much of Pfizer's revenue is driven by therapies with only modest competition. This stock is also developing a very impressive dividend-growth track record.

Fool | 1 year ago
Down 55%, Is Pfizer a Good Dividend Stock to Buy on the Dip?

Down 55%, Is Pfizer a Good Dividend Stock to Buy on the Dip?

Despite a tanking stock price, Pfizer has raised its dividend for 15 consecutive years. Pfizer's profits are off their peak but more than sufficient to continue raising the dividend.

Fool | 1 year ago
Pfizer (PFE) Stock Falls in a Year: Time to Buy, Sell or Hold?

Pfizer (PFE) Stock Falls in a Year: Time to Buy, Sell or Hold?

Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.

Zacks | 1 year ago
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes

Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes

Pharmaceutical giant Pfizer Inc. NYSE: PFE has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy makers Novo Nordisk A/S NYSE: NVO and Mounjaro and Zepbound makers Eli Lilly & Co. NYSE: LLY. Pfizer had failed in its previous attempts to create a viable GLP-1 contender.

Marketbeat | 1 year ago
1 Underwhelming Stat That May Have You Thinking Twice About Buying Pfizer's Stock

1 Underwhelming Stat That May Have You Thinking Twice About Buying Pfizer's Stock

Pfizer is in the midst of transition as it faces multiple patent cliffs. The company's growth strategy suggests that the business could be bigger by the end of the decade, but not necessarily by a whole lot.

Fool | 1 year ago
UK court gives mixed ruling in Pfizer v Moderna COVID vaccine patents case

UK court gives mixed ruling in Pfizer v Moderna COVID vaccine patents case

London's High Court on Tuesday ruled that one of Moderna's patents relating to technology key to the development of vaccines for COVID-19 was invalid, but that another was valid and had been infringed by Pfizer and BioNTech's rival vaccine.

Reuters | 1 year ago
Pfizer: It Could Be A Bargain

Pfizer: It Could Be A Bargain

When excluding sales Pfizer generated due to COVID-19 vaccines and medication, the business is reporting solid growth. Especially the oncology business will drive growth in the years to come, and the Seagan acquisition might also contribute. With its high dividend yield and rather undervalued stock, PFE stock is a "Buy" at this point.

Seekingalpha | 1 year ago
Pfizer And Moderna Vaccines Not Linked To Birth Defects, Study Finds

Pfizer And Moderna Vaccines Not Linked To Birth Defects, Study Finds

There is no evidence of major birth defects in babies born to mothers vaccinated against COVID-19 during the first trimester of pregnancy, according to new research published in JAMA Pediatrics on Monday, underscoring the safety of vaccination during pregnancy amid mounting evidence of the severe health risks infections can cause for mothers and babies.

Forbes | 1 year ago
Pfizer (PFE), BioNTech's Updated COVID-19 Jab Gets CHMP Nod

Pfizer (PFE), BioNTech's Updated COVID-19 Jab Gets CHMP Nod

Pfizer (PFE) and BioNTech's Omicron JN.1-adapted COVID-19 vaccine gets the Committee for Medicinal Products for Human Use's positive opinion recommending marketing authorization.

Zacks | 1 year ago
Pfizer struggles to claw back faith with Wall Street and its employees as it recovers from the Covid decline

Pfizer struggles to claw back faith with Wall Street and its employees as it recovers from the Covid decline

Pfizer appears to be on its way toward stabilizing its business and winning back Wall Street's favor after the sudden decline of its Covid business. But the company is struggling to balance that with the concerns and fears of its workers.

Cnbc | 1 year ago
Is Pfizer Stock a Buy?

Is Pfizer Stock a Buy?

Pfizer shares have suffered a painful slide as pandemic revenue dried up. But management is committed to maintaining and growing the dividend.

Fool | 1 year ago
2 Healthcare Stocks That Are Screaming Buys in June

2 Healthcare Stocks That Are Screaming Buys in June

A rare-disease drugmaker and a top pharmaceutical stock have what it takes to deliver solid returns over the long run. Vertex Pharmaceuticals' flagship business continues to expand market share and profits.

Fool | 1 year ago
Loading...
Load More